Pioneer Pharma Completes $2.5 Million Investment in NovaBay
publication date: Nov 5, 2012
Pioneer Pharma, a Singapore company that is affiliated with Naqu Area Pioneer Pharma of Shanghai, completed a $2.5 million investment into California-based NovaBay® Pharma. The investment was part of deal that gives Pioneer the right to market NovaBay’s anti-infective wound-cleaning product, NeutroPhase, in China and Southeast Asia. The investment purchased two million units at a price of $1.25 each. Each unit consists of one share of NovaBay and a warrant to buy an additional share at a price of $1.50. NovaBay is currently trading at $1.31. More details....
Stock Symbol: (NYSE: NBY)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.